Investigational and Established Biomarkers Guide Ongoing CRPC Therapy Developments
Evan Y. Yu, MD, discusses future directions for biomarker research and targeted therapy development for patients with castration-resistant prostate cancer.
Related Articles
Targeted CAR T-Cell Therapies Show Early Efficacy in Solid Tumors With Focus on Mitigating Toxicity
Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell agents in patients with solid tumors.
Avutometinib/Defactinib Expands Treatment Options for KRAS-Mutant Low-Grade Serous Ovarian Cancer
Bradley Monk, MD, FACOG, FACS, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment
Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.
Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung
Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.
ADCs Are Poised to Transform the Metastatic TNBC Treatment Arsenal
Nerea Lopetegui-Lia, MD, discusses ongoing trials investigating ADCs that are shaking up the metastatic triple-negative breast cancer setting.
Cyclin E1 Positivity May Enhance Patient Selection for Azenosertib in Platinum-Resistant Ovarian Cancer
Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.
Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC
Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.
Dr Monk on the FDA Approval of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Talazoparib/Enzalutamide Combo, Radioligand Therapy Expand Options in mCRPC
Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.
Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making
Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.